RE:RE:RE:RE:RE:RE:RE:$45/sh tomorrow?There are certainly sector issues at play but there will always be a need to buy healthcare exposure for most money managers. The smart thing to do is look at where the money is most likely to flow in the sector. Almost every other name is toxic right now. Vrx has many issues with negative headlines, shorts etc., Nhc has shorts and a death kiss of postponed financials, anything to do with Dalsin is toxic. Most legacy pharma companies have broken models due to low trading multiples crippling their ability to raise capital to buy. Right now cxr is the most logical choice for any fund managet looking for a reasonably liquid stock, at a great valuation with next years growth already built in.